141 related articles for article (PubMed ID: 35247898)
21. Ovarian Cancer-Intrinsic Fatty Acid Synthase Prevents Anti-tumor Immunity by Disrupting Tumor-Infiltrating Dendritic Cells.
Jiang L; Fang X; Wang H; Li D; Wang X
Front Immunol; 2018; 9():2927. PubMed ID: 30619288
[TBL] [Abstract][Full Text] [Related]
22. WNT/β-Catenin Signaling Pathway Regulating T Cell-Inflammation in the Tumor Microenvironment.
Li X; Xiang Y; Li F; Yin C; Li B; Ke X
Front Immunol; 2019; 10():2293. PubMed ID: 31616443
[TBL] [Abstract][Full Text] [Related]
23. Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomes.
Ligon JA; Choi W; Cojocaru G; Fu W; Hsiue EH; Oke TF; Siegel N; Fong MH; Ladle B; Pratilas CA; Morris CD; Levin A; Rhee DS; Meyer CF; Tam AJ; Blosser R; Thompson ED; Suru A; McConkey D; Housseau F; Anders R; Pardoll DM; Llosa N
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34021032
[TBL] [Abstract][Full Text] [Related]
24. The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy.
Palazón A; Martínez-Forero I; Teijeira A; Morales-Kastresana A; Alfaro C; Sanmamed MF; Perez-Gracia JL; Peñuelas I; Hervás-Stubbs S; Rouzaut A; de Landázuri MO; Jure-Kunkel M; Aragonés J; Melero I
Cancer Discov; 2012 Jul; 2(7):608-23. PubMed ID: 22719018
[TBL] [Abstract][Full Text] [Related]
25. The Crowded Crosstalk between Cancer Cells and Stromal Microenvironment in Gynecological Malignancies: Biological Pathways and Therapeutic Implication.
De Nola R; Menga A; Castegna A; Loizzi V; Ranieri G; Cicinelli E; Cormio G
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31096567
[TBL] [Abstract][Full Text] [Related]
26. Resident Memory T Cells in the Tumor Microenvironment.
Williams JB; Kupper TS
Adv Exp Med Biol; 2020; 1273():39-68. PubMed ID: 33119875
[TBL] [Abstract][Full Text] [Related]
27. Recruiting T cells in cancer immunotherapy.
Yost KE; Chang HY; Satpathy AT
Science; 2021 Apr; 372(6538):130-131. PubMed ID: 33833111
[No Abstract] [Full Text] [Related]
28. VISTA expressed in tumour cells regulates T cell function.
Mulati K; Hamanishi J; Matsumura N; Chamoto K; Mise N; Abiko K; Baba T; Yamaguchi K; Horikawa N; Murakami R; Taki M; Budiman K; Zeng X; Hosoe Y; Azuma M; Konishi I; Mandai M
Br J Cancer; 2019 Jan; 120(1):115-127. PubMed ID: 30382166
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy.
Lo CS; Sanii S; Kroeger DR; Milne K; Talhouk A; Chiu DS; Rahimi K; Shaw PA; Clarke BA; Nelson BH
Clin Cancer Res; 2017 Feb; 23(4):925-934. PubMed ID: 27601594
[No Abstract] [Full Text] [Related]
30. The influence of microenvironment on tumor immunotherapy.
Zhang J; Shi Z; Xu X; Yu Z; Mi J
FEBS J; 2019 Nov; 286(21):4160-4175. PubMed ID: 31365790
[TBL] [Abstract][Full Text] [Related]
31. The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy.
Lim AR; Rathmell WK; Rathmell JC
Elife; 2020 May; 9():. PubMed ID: 32367803
[TBL] [Abstract][Full Text] [Related]
32. Immunometabolism: A new target for improving cancer immunotherapy.
Guo C; Chen S; Liu W; Ma Y; Li J; Fisher PB; Fang X; Wang XY
Adv Cancer Res; 2019; 143():195-253. PubMed ID: 31202359
[TBL] [Abstract][Full Text] [Related]
33. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
34. Strategies to Improve the Antitumor Effect of γδ T Cell Immunotherapy for Clinical Application.
Miyashita M; Shimizu T; Ashihara E; Ukimura O
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445615
[TBL] [Abstract][Full Text] [Related]
35. Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity.
Pai CS; Simons DM; Lu X; Evans M; Wei J; Wang YH; Chen M; Huang J; Park C; Chang A; Wang J; Westmoreland S; Beam C; Banach D; Bowley D; Dong F; Seagal J; Ritacco W; Richardson PL; Mitra S; Lynch G; Bousquet P; Mankovich J; Kingsbury G; Fong L
J Clin Invest; 2019 Jan; 129(1):349-363. PubMed ID: 30530991
[TBL] [Abstract][Full Text] [Related]
36. Fundamentals of T Cell Metabolism and Strategies to Enhance Cancer Immunotherapy.
Rangel Rivera GO; Knochelmann HM; Dwyer CJ; Smith AS; Wyatt MM; Rivera-Reyes AM; Thaxton JE; Paulos CM
Front Immunol; 2021; 12():645242. PubMed ID: 33815400
[TBL] [Abstract][Full Text] [Related]
37. Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy?
Gargiulo P; Della Pepa C; Berardi S; Califano D; Scala S; Buonaguro L; Ciliberto G; Brauchli P; Pignata S
Cancer Treat Rev; 2016 Jul; 48():61-8. PubMed ID: 27362548
[TBL] [Abstract][Full Text] [Related]
38. Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity.
Chen ML; Yan BS; Lu WC; Chen MH; Yu SL; Yang PC; Cheng AL
Int J Cancer; 2014 Jan; 134(2):319-31. PubMed ID: 23818246
[TBL] [Abstract][Full Text] [Related]
39. Association of Germline Variants in Natural Killer Cells With Tumor Immune Microenvironment Subtypes, Tumor-Infiltrating Lymphocytes, Immunotherapy Response, Clinical Outcomes, and Cancer Risk.
Xu X; Li J; Zou J; Feng X; Zhang C; Zheng R; Duanmu W; Saha-Mandal A; Ming Z; Wang E
JAMA Netw Open; 2019 Sep; 2(9):e199292. PubMed ID: 31483464
[TBL] [Abstract][Full Text] [Related]
40. The Immune Subtypes and Landscape of Gastric Cancer and to Predict Based on the Whole-Slide Images Using Deep Learning.
Chen Y; Sun Z; Chen W; Liu C; Chai R; Ding J; Liu W; Feng X; Zhou J; Shen X; Huang S; Xu Z
Front Immunol; 2021; 12():685992. PubMed ID: 34262565
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
